Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Survival Without Progression × Cyclophosphamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 544 Lymphoma 443 Precursor Cell Lymphoblastic Leukemia-Lymphoma 407 Lymphoma, Large B-Cell, Diffuse 346 Leukemia 343 Multiple Myeloma 334 Lymphoma, Non-Hodgkin 313 Leukemia, Lymphocytic, Chronic, B-Cell 285 Leukemia, Myeloid, Acute 283 Lymphoma, Follicular 240 Burkitt Lymphoma 217 Myelodysplastic Syndromes 207 Lymphoma, Mantle-Cell 200 Hodgkin Disease 192 Recurrence 151 Lymphoma, B-Cell, Marginal Zone 142 Melanoma 134 Lymphoma, Large-Cell, Immunoblastic 116 Neoplasms 109 Neuroblastoma 101 Lymphoma, B-Cell 100 Neoplasms, Plasma Cell 99 Triple Negative Breast Neoplasms 93 Ovarian Neoplasms 93 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91 Myeloproliferative Disorders 87 Hematologic Neoplasms 86 Leukemia, Myeloid, Chronic-Phase 83 Leukemia, Myeloid, Accelerated Phase 80 Leukemia, Myelomonocytic, Chronic 77

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡